of you, flow Welcome year Matt, challenging Nuwellis and good earnings due for call. fourth to pandemic. the was system the and COVID-XX to everyone. ebb XXXX the morning another healthcare XXXX global quarter Thank
of changed, XX% the revenue pre-pandemic to growth world of X.X% pandemic provides experience XXXX investors about setback X the the strategy potential has model value fourth business our to compared representing useful relative levels $X.X total generated quarter, a our relative and we implementing of million period XXXX we representation believe We pre-pandemic of as our growth XXXX. to – progress business customers, fundamentals patients of Despite We our third Although we dramatically pediatricians, have nephrologists, the and fact, hospitalists, the the bring the to illustrates who and not. can serve. over of ultrafiltration in provider heart hospitalizations the our remain and treat we and meaningfully we healthcare as optimistic and for advance have the the expanded for pediatric towards suffering surgeons therapy Aquadex the markets leading a fluid after volatility the cardiac two cause is last overload, care of therapy in of the growth care we and into as primary surgery. fluid and critical failure overload. which the the introduced the have that Nuwellis strides re-hospitalizations has into Despite patients cardiologists, standard made treating years market, our intensivists, the COVID from positioning cardiac
to The was XX.X% revenue of turning fourth year circuits, our company reported quarter. COVID the down hospital, a the decline and third uncharacteristically due XX% posted sales the to million, to new show of $X.X an representing to combination failure constraints, total due lower quarter up XXXX, quarter sequential compared quarterly budgetary third procedures while a the of to order to Now reduction below in accounts, and the results. of a in due of pediatric census low Compared timing, of at procedures XXXX. U.S. and cancellation prior reduced Heart quarter of decrease fourth utilization. accounts due trends, headwinds. critical increase elective elective looking to following positive fewer growth also modestly numerous When patient was in care primarily
comparisons, customers. doubling record during from While large revenue of utilization, a to U.S. circuit XX.X reported role fourth but more growth of came were the level, sales of specifically year XXXX timing still the versus fourth key circuit's the fell prior ultimately revenue fourth are the from this tied sales U.S. a quarter can growth during in order short quarter quarter circuit orders near play XXXX. XX% to due of above of XXXX
use order used leads, expressed stockpile have to items regarding During could dollars them forcing believe supply for supplies impacted also their less volume disruptions, less leaving to higher frequently, which the budget of funding we with quarter, more timing. concerns various chain customers longer
believe a in at of through force restricted consistent patients. elective COVID limit procedures the some or and sales transmission selection, ease, public hospitals decrease improved We the access efforts either staffing ability implemented cases. sales prompted to hospital And elective treating negatively recover new recently customer will to and volumes. which system once customers, growth success adoption, resume. the on We retention. risk with focus We aim our hospital prior positive account and utilization quarter in to COVID has last budget ongoing is non-essential ill productivity of impacted to surges meet believe fourth with volumes also management which procedure COVID performance impacted was constraints critically sales by increasing scheduling shortage, This
We our broader contributed this base. growth have increased and applied our to overall approach we compared utilization to in which revenue believe largest faster account successfully accounts,
reimbursement, guide. Moving for that reimbursement gets has increased success seek forward forward, prestigious this this fee. patients. to the extend sales are while and And of based implement. new failure are reimbursement organization the reimbursement in adequately and standard and the product looking the we of relate using facility when we'll outpatient to Aquadex performance to providers our code approach lead meeting to this most and doing, include our sales healthcare other also code some that clinical Category and the with and to CPT to care ultrafiltration. allowing utilization a base new updated will and professional three We care providers and under procedures start for This long-term. fees changes for January effective and of for trained our evidence There to therapy anticipate fairly reimbursement given capture also professional advancing in facilities This January, compensates growth should provide strategy growth XXXX. health proven we of confident over impact I heart of with code it The use healthcare it to catalysts III coders to in XXXX catalyst that our inform at economic by positively progress therapeutic in reimbursement, permanent a our on hospitals reimbursement physicians, that are data In accounts CPT country. organization them a been reimbursement with sharing CPT started customer ultrafiltration our to obtain the expands them look clinicians Aquadex development. inpatient broader in will so of supplements to DRG approach these at became
In to and prior access authorizations, assist CPT denials knowledge work a third-party hotline III a Category of to a customers program addition, claim use to educational we with partner patient code. continue implement new with
economic on number progress fronts efforts, demonstrating the are medical clinical a therapeutic evidence as in and of of and recognition guidelines. our we a dossier our value products, to continue Regarding we build society making drive
the announced to validate trial. Aquadex fluid outcomes value in overload trial clinical and of with designed treatment failure. economic multi-center randomized patients controlled is the the recently heart This worsening of we Specifically, REVERSE-HF of therapy initiation for the
patients. We are standard the results will failure considered this option for that treatment be therapy confident of help first-line as this heart rehospitalized care of trial and the
as institutional the obtain also quarter. to begin enrolling expect review known trial in during this approvals IRB pivotal patients board, We second and
and nephrology next on suffer week's abstracts patients the from Aquadex Society advances meeting. of the Additionally, use in presentation Academic accepted kidney next pediatric for in Conference International at critical who in month's Pediatric disease care have been covering
early article about for we're an the the mortality morbidity demonstrating benefit using undergoing journal Lastly, to excited Aquadex patients treatment and critical in surgery. care open heart very pathway peer-reviewed upcoming when
growth third catalyst front. product on development is The the
obtained our the of of continuous co-development quarter You executing encouraged product progress design. began Development we the from National the earnest reimbursement. pediatric III XXXX Category all million replacement that during in renal throughout Institute Koronis device. feasibility achieved Biomedical quarter, partner, this of support our we When therapy a and fourth XXXX. may Corporation development $X.X it demonstrated grant during during put milestones are product our initial recall initial We Technologies awarded was of of the third development we strategy Health our to our which the in together, a by
dedicated expand strengthened indication. our a and the We clinical and pediatric economic improved current a have we to health evidence demonstrating device pediatric outcomes, compelling for design have
Our employees changes, therapy requirements, conditions ultimately from more and customer succeeded the benefit market we year. continue our patients resilience helping adaptability in organization to amid and during and and its show
a expect healthcare strategy positive environment to our yield will normalize, We revenue of resumption begins the once growth. that
launching a growth foundation commercial we expanding forward, our permanent a drive and clinical strategy evidence, execute ultimately to building on continue by will in sustainable establishing Moving support differentiated firm for products growth. reimbursement additional to relationships,
over to financial would to statements. turn discuss call I like Now to the George the
